Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers

被引：102

作者：

Offin, Michael ^{[1
,2
]}

Somwar, Romel ^{[1
]}

Rekhtman, Natasha ^{[1
]}

Benayed, Ryma ^{[1
]}

Chang, Jason C. ^{[1
]}

Plodkowski, Andrew ^{[1
]}

Lui, Allan J. W. ^{[1
,3
]}

Eng, Juliana ^{[1
,2
]}

Rosenblum, Marc ^{[1
]}

Li, Bob T. ^{[1
,2
]}

Riely, Gregory J. ^{[1
,2
]}

Rudin, Charles M. ^{[1
,2
]}

Kris, Mark G. ^{[1
,2
]}

Travis, William ^{[1
]}

Drilon, Alexander ^{[1
,2
]}

Arcila, Maria E. ^{[1
]}

Ladanyi, Marc ^{[1
]}

Yu, Helena A. ^{[1
,2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 300 E 66th St, New York, NY 10065 USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Chinese Univ Hong Kong, Sha Tin New Town, Hong Kong, Peoples R China

来源：

JCO PRECISION ONCOLOGY | 2018年 / 2卷

基金：

美国国家卫生研究院;

关键词：

TYROSINE KINASE INHIBITORS; MUTATION;

D O I：

10.1200/PO.18.00126

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：1 / 12

页数：12

共 23 条

[1] In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET [J].

Arai, Sachiko ;

Kita, Kenji ;

Tanimoto, Azusa ;

Takeuchi, Shinji ;

Fukuda, Koji ;

Sato, Hiroshi ;

Yano, Seiji .

ONCOTARGET, 2017, 8 (43) :73766-73773

[2] Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients [J].

Chabon, Jacob J. ;

Simmons, Andrew D. ;

Lovejoy, Alexander F. ;

Esfahani, Mohammad S. ;

Newman, Aaron M. ;

Haringsma, Henry J. ;

Kurtz, David M. ;

Stehr, Henning ;

Scherer, Florian ;

Karlovich, Chris A. ;

Harding, Thomas C. ;

Durkin, Kathleen A. ;

Otterson, Gregory A. ;

Purcell, W. Thomas ;

Camidge, D. Ross ;

Goldman, Jonathan W. ;

Sequist, Lecia V. ;

Piotrowska, Zofia ;

Wakelee, Heather A. ;

Neal, Joel W. ;

Alizadeh, Ash A. ;

Diehn, Maximilian .

NATURE COMMUNICATIONS, 2016, 7

[3] Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology [J].

Cheng, Donavan T. ;

Mitchell, Talia N. ;

Zehir, Ahmet ;

Shah, Ronak H. ;

Benayed, Ryma ;

Syed, Aijazuddin ;

Chandramohan, Raghu ;

Liu, Zhen Yu ;

Won, Helen H. ;

Scott, Sasinya N. ;

Brannon, A. Rose ;

O'Reilly, Catherine ;

Sadowska, Justyna ;

Casanova, Jacklyn ;

Yannes, Angela ;

Hechtman, Jaclyn F. ;

Yao, Jinjuan ;

Song, Wei ;

Ross, Dara S. ;

Oultache, Alifya ;

Dogan, Snjezana ;

Borsu, Laetitia ;

Hameed, Meera ;

Nafa, Khedoudja ;

Arcila, Maria E. ;

Ladanyi, Marc ;

Berger, Michael F. .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (03) :251-264

[4] Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib [J].

Ho, Chao-Chi ;

Liao, Wei-Yu ;

Lin, Chih-An ;

Shih, Jin-Yuan ;

Yu, Chong-Jen ;

Yang, James Chih-Hsin .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (03) :567-572

[5] Acquired Resistance to Osimertinib by CCDC6-RET Fusion in a Patient with EGFR T790M Mutant Metastatic Lung Adenocarcinoma [J].

Iams, W. ;

Chae, Y. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S2249-S2250

[6] Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer [J].

Jackman, David ;

Pao, William ;

Riely, Gregory J. ;

Engelman, Jeffrey A. ;

Kris, Mark G. ;

Jaenne, Pasi A. ;

Lynch, Thomas ;

Johnson, Bruce E. ;

Miller, Vincent A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) :357-360

[7] Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial [J].

Jaenne, Pasi A. ;

Wang, Xiaofei ;

Socinski, Mark A. ;

Crawford, Jeffrey ;

Stinchcombe, Thomas E. ;

Gu, Lin ;

Capelletti, Marzia ;

Edelman, Martin J. ;

Villalona-Calero, Miguel A. ;

Kratzke, Robert ;

Vokes, Everett E. ;

Miller, Vincent A. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2063-2069

[8] Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies [J].

Jordan, Emmet J. ;

Kim, Hyunjae R. ;

Arcila, Maria E. ;

Barron, David ;

Chakravarty, Debyani ;

Gao, JianJiong ;

Chang, Matthew T. ;

Ni, Andy ;

Kundra, Ritika ;

Jonsson, Philip ;

Jayakumaran, Gowtham ;

Gao, Sizhi Paul ;

Johnsen, Hannah C. ;

Hanrahan, Aphrothiti J. ;

Zehir, Ahmet ;

Rekhtman, Natasha ;

Ginsberg, Michelle S. ;

Li, Bob T. ;

Yu, Helena A. ;

Paik, Paul K. ;

Drilon, Alexander ;

Hellmann, Matthew D. ;

Reales, Dalicia N. ;

Benayed, Ryma ;

Rusch, Valerie W. ;

Kris, Mark G. ;

Chaft, Jamie E. ;

Baselga, Jose ;

Taylor, Barry S. ;

Schultz, Nikolaus ;

Rudin, Charles M. ;

Hyman, David M. ;

Berger, Michael F. ;

Solit, David B. ;

Ladanyi, Marc ;

Riely, Gregory J. .

CANCER DISCOVERY, 2017, 7 (06) :596-609

[9]

Klempner SJ, 2017, LUNG CANCER-TARGETS, V8, P241, DOI 10.2147/LCTT.S147129

[10] Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations [J].

Li, Gang G. ;

Somwar, Romel ;

Joseph, James ;

Smith, Roger S. ;

Hayashi, Takuo ;

Martin, Leenus ;

Franovic, Aleksandra ;

Schairer, Anni ;

Martin, Eric ;

Riely, Gregory J. ;

Harris, Jason ;

Yan, Shunqi ;

Wei, Ge ;

Oliver, Jennifer W. ;

Patel, Rupal ;

Multani, Pratik ;

Ladanyi, Marc ;

Drilon, Alexander .

CLINICAL CANCER RESEARCH, 2017, 23 (12) :2981-2990

← 1 2 3 →